Sodium-glucose co-transporter 2 (SGLT2) inhibitors for treating type 2 diabetes mellitus

Published on 03 May 2017
Last Updated on 02 Jan 2024

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

• Empagliflozin 10 mg and 25 mg tablets

in line with its registered indication for treating type 2 diabetes mellitus, in view of favourable clinical and cost-effectiveness.

Subsidy status

Empagliflozin 10 mg and 25 mg tablets are recommended for inclusion on the Standard Drug List (SDL) from 1 November 2023.

Of note, dapagliflozin 5 mg and 10 mg tablets will be delisted from the MOH List of Subsidised Drugs with effect from 1 August 2024 due to unfavourable cost-effectiveness compared with empagliflozin. Subsidy does not apply to any formulations or strengths of canagliflozin.

SGLT2 inhibitors for treating type 2 diabetes mellitus (Updated 2 Jan 2024) [PDF, 308 KB]